Stanford Cancer Center

Developmental Therapeutics CRG

Click here to print this page (PDF)

23 April 2015

Solid Tumors

Phase 1

VAR0113
Phase I Dose Escalation Trial of Hu5F9-G4 in Advanced Solid Malignancies

PI: Sikic
Stanford

1st Priority

LYMNHL0092
Phase I PF-05082566 as a Single Agent in patients w/ relapsed / refractory solid tumors or B cell lymphoma (Portion A arm)

PI: Levy
Pfizer

2nd Priority

VAR0071
Phase I Study BMS-663513 (Anti-CD137) in Advanced and/or Metastatic Solid Tumors

PI: Levy
Bristol Myers-Squibb

4rd Priority

VAR0082
Phase I MPDL3280A Administered IV as a Single Agent in Locally Advanced or Metastatic Solid Tumors

PI: Fisher
Genentech

4th Priority

VAR0093
Phase I Recombinant Human IL15 (rhIL15) in Melanoma/ Renal Cell/ Non-Small Cell Lung/ Head & Neck CA

PI: Wakelee
CITN

5th Priority

Squamous Cell or Colorectal

VAR0106
Phase 1b Urelumab + Cetuximab in Advanced / Metastatic CRC or SCCHN

PI: Colevas
Bristol-Myers Squibb

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link Trial Posting
- Enrollment on Hold
- Extension Study

Please mark up a copy using black ink and fax changes to 725-9204